A multinational research team led by Professor Małgorzata Kujawska at the Poznań University of Medical Sciences in Poland has discovered that graphene quantum dots (GQDs) can interfere with the aggregation of misfolded α-synuclein (ASN) protein, a hallmark of synucleinopathies such as Parkinson's disease and multiple system atrophy (MSA). The study, published in the journal Science and Technology of Advanced Materials, details how these nanoscale carbon particles prevent ASN from forming toxic fibers that lead to neuronal loss.
Current treatments for synucleinopathies only manage symptoms rather than stopping the underlying protein clumping. The researchers tested GQDs in cell-free environments, neuronal cultures, and animal models of MSA. When administered intranasally in mice, the particles significantly reduced the presence of toxic protein aggregates. The treatment appeared to activate autophagy, a cellular recycling process that helps remove damaged proteins. At biologically relevant concentrations, the GQDs showed a favorable safety profile, though higher doses caused some changes in cellular stress and immune responses.
"This study points to a promising new direction for strategies against neurodegenerative diseases," said Professor Kujawska. "While clinical use of GQDs remains a long way off, these findings strengthen the case for further research." Challenges remain, including preventing quantum dots from clumping in liquid suspensions. "GQDs may serve as a useful research tool," Kujawska added. "What we learn as we optimize their properties and conduct a comprehensive safety evaluation could help design more effective nanomaterial-based strategies not just for synucleinopathies, but also for other conditions characterized by the buildup of toxic proteins."
The study highlights the potential of engineered carbon-based nanomaterials in targeting neurodegenerative diseases. Further research is needed to address biocompatibility and delivery challenges before GQDs can be considered for clinical use.
